Article
Environmental Sciences
Chentao Xu, Jincheng Cao, Tianjin Zhou
Summary: This study reveals the prognostic characteristics of angiogenesis-related genes in bladder cancer and provides insights for exploring more effective immunotherapy strategies. The findings have significant implications for the development of personalized treatment approaches in bladder cancer.
ENVIRONMENTAL TOXICOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Paulina Wigner, Radoslaw Grebowski, Michal Bijak, Joanna Saluk-Bijak, Janusz Szemraj
Summary: Bladder cancer is a dangerous disease, with men being at higher risk and risk factors including chemical exposure and genetic factors. Studies suggest that inflammation, oxidative stress, and angiogenesis disorders may promote the development of bladder cancer, and gene polymorphisms may affect the risk of the disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell Biology
Mariantonia Braile, Simone Marcella, Gianni Marone, Maria Rosaria Galdiero, Gilda Varricchi, Stefania Loffredo
Summary: Cannabis activates the CB1 and CB2 receptors to modulate various aspects of cancer cells, while immune cells in the tumor microenvironment play a central role in tumor initiation and growth. The recent characterization of the human cannabinoid receptor CB2-G(i) signaling complex may aid in designing potent and specific CB2/CB1 ligands for cancer therapy.
Review
Biochemistry & Molecular Biology
Mathilde Cancel, William Pouillot, Karine Maheo, Alix Fontaine, David Crottes, Gaelle Fromont
Summary: Adipose tissue, both periprostatic and metastatic sites, plays a role in prostate cancer aggressiveness through various molecular interactions. The effects on cancer cells may depend on the balance between pro- and anti-tumor components of the tissue. Genetic and environmental factors like obesity and diet can modulate these interactions and impact the growth and metastatic potential of prostate cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Dallin Lowder, Kinza Rizwan, Collin McColl, Alyssa Paparella, Michael Ittmann, Nicholas Mitsiades, Salma Kaochar
Summary: Prostate cancer has the largest health disparity in the US, with Black men having a significantly higher risk of dying from prostate cancer compared to other races. This disparity is influenced by factors such as socioeconomic status, environmental exposures, and genetics/biology. While improving healthcare access is important, it will not fully eliminate racial health disparities in prostate cancer outcomes. Biology also plays a crucial role, with significant differences observed in prostate cancer biology between ancestral groups.
Review
Biochemistry & Molecular Biology
Sameera Kumar, Daret St Clair
Summary: Prostate cancer is common in men, and oxidative stress caused by free radicals and reactive oxygen species could be a contributing factor. The superoxide dismutase family plays a crucial role in removing oxygen-derived reactive oxygen species, and increased superoxide dismutase activity may have a protective effect against prostate cancer. Understanding the role of superoxide dismutase in radioresistance has led to the development of interventions targeting the NF-kappa B pathway for prostate cancer treatment.
Article
Cell Biology
Raymond Mario Barry, Olivia Sacco, Amel Mameri, Martin Stojaspal, William Kartsonis, Pooja Shah, Pablo De Ioannes, Ctirad Hofr, Jacques Cote, Agnel Sfeir
Summary: This study uncovers the mechanism of gene expression regulation by the telomere binding protein Rap1. Rap1 interacts with the TIP60/p400 complex and modulates its histone acetyltransferase activity. Deletion of Rap1 increases the fraction of two-cell-like cells in mouse embryonic stem cells and leads to upregulation of certain genes.
GENES & DEVELOPMENT
(2022)
Article
Multidisciplinary Sciences
Joanna Lazniewska, Ka Lok Li, Ian R. D. Johnson, Alexandra Sorvina, Jessica M. Logan, Carmela Martini, Courtney Moore, Ben S. -Y. Ung, Litsa Karageorgos, Shane M. Hickey, Sarita Prabhakaran, Jessica K. Heatlie, Robert D. Brooks, Chelsea Huzzell, Nicholas I. Warnock, Mark P. Ward, Bashir Mohammed, Prerna Tewari, Cara Martin, Sharon O'Toole, Laura Bogue Edgerton, Mark Bates, Paul Moretti, Stuart M. Pitson, Stavros Selemidis, Lisa M. Butler, John J. O'Leary, Douglas A. Brooks
Summary: The development and progression of prostate cancer are closely related to the regulation of glucose and lipid metabolism, as well as alterations in androgen receptor expression and signaling. This study reveals a previously unrecognized molecular mechanism for prostate cancer, which involves the dynamic balance between sortilin and syndecan-1 and their impact on different metabolic phenotypes. In androgen-sensitive cells, sortilin enhances glucose metabolism while limiting lipid metabolism, whereas in androgen-insensitive cells, syndecan-1 promotes lipid metabolism. Additionally, androgen-deprived cells show decreased expression of sortilin and increased expression of syndecan-1, contributing to altered glucose and lipid metabolism. These findings have important implications for understanding disease progression and castration-resistant prostate cancer in the context of androgen-deprivation therapy.
SCIENTIFIC REPORTS
(2023)
Article
Cell Biology
Naidi Yang, Dipanwita Das, Shilpa Rani Shankar, Pierre-Alexis Goy, Ernesto Guccione, Reshma Taneja
Summary: A relationship between BRD4 and G9a in the regulation of myogenic differentiation through histone modifications has been identified. BRD4 depletion upregulates G9a activity and impairs myogenic differentiation.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biology
Brigida Anna Maiorano, Alessandro Parisi, Evaristo Maiello, Davide Ciardiello
Summary: Colorectal cancer is a common and deadly tumor, where angiogenesis and immune modulation play crucial roles in development. By combining anti-angiogenic drugs and immune checkpoint inhibitors, the treatment efficacy can be enhanced.
Article
Medicine, Research & Experimental
Elmira Roshani Asl, Mohammad Amini, Souzan Najafi, Behzad Mansoori, Ahad Mokhtarzadeh, Ali Mohammadi, Parisa Lotfinejad, Mehdi Bagheri, Solmaz Shirjang, Ziba Lotfi, Yousef Rasmi, Behzad Baradaran
Summary: The highly conserved MAPK signal transduction pathway plays a crucial role in cancer progression, while miRNAs act as critical regulators in cancer initiation and progression. The interaction between miRNAs and the MAPK signaling pathway is pivotal in the development of human cancers.
Review
Oncology
Reema Singh, Ian G. Mills
Summary: Prostate cancer is a high-incidence cancer linked to increased mitochondrial metabolic activity. Genomic drivers such as the androgen receptor, c-Myc, PTEN, and p53 are associated with metabolic dysregulation and progression of prostate cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Marco Del Giudice, John G. Foster, Serena Peirone, Alberto Rissone, Livia Caizzi, Federica Gaudino, Caterina Parlato, Francesca Anselmi, Rebecca Arkell, Simonetta Guarrera, Salvatore Oliviero, Giuseppe Basso, Prabhakar Rajan, Matteo Cereda
Summary: FOXA1 plays a key role in dysregulation of alternative splicing in prostate cancer by controlling transcription factor expression and binding to splicing-related genes, leading to the production of dominant isoforms and influencing patient survival.
Review
Oncology
Lu Yao, Xiangyu Zhang
Summary: Prostate cancer is a common cancer that poses a serious threat with bone metastasis and drug resistance. The theoretical model of cancer stem cells explains the characteristics and challenges of cancer. Targeting cancer stem cells might be more effective in overcoming drug resistance and metastasis.
Article
Biochemistry & Molecular Biology
Marc Kenneth M. Cajili, Eloise Prieto
Summary: This study investigated the role of archaeal architectural proteins Alba and Cren7 in chromatin folding and dynamics. The results showed that Alba can mediate the formation of folded DNA structures to regulate chromatin compaction, while Cren7 affects the formation of Alba-mediated higher-order chromatin structures.
Article
Pharmacology & Pharmacy
Frank Hilberg, Ulrike Tontsch-Grunt, Anke Baum, Anh T. Le, Robert C. Doebele, Simone Lieb, Davide Gianni, Tilman Voss, Pilar Garin-Chesa, Christian Haslinger, Norbert Kraut
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2018)
Article
Oncology
Kasey L. Couts, Judson Bemis, Jacqueline A. Turner, Stacey M. Bagby, Danielle Murphy, Jason Christiansen, Jennifer D. Hintzsche, Anh Le, Todd M. Pitts, Keith Wells, Allison Applegate, Carol Amato, Pratik Multani, Edna Chow-Maneval, John J. Tentler, Yiqun G. Shellman, Matthew J. Rioth, Aik-Choon Tan, Rene Gonzalez, Theresa Medina, Robert C. Doebele, William A. Robinson
MOLECULAR CANCER THERAPEUTICS
(2018)
Editorial Material
Pharmacology & Pharmacy
Caroline E. McCoach, Robert C. Doebele
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2018)
Meeting Abstract
Oncology
Laura Schubert, Anh T. Le, Stephen P. Malkoski, Raphael Nemenoff, Robert C. Doebele
Article
Oncology
Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D. Davies, Daniel T. Merrick, Paul A. Bunn, W. Tom Purcell, Rafal Dziadziuszko, Marileila Varella-Garcia, Dara L. Aisner, D. Ross Camidge, Robert C. Doebele
CLINICAL CANCER RESEARCH
(2018)
Article
Oncology
Caroline E. McCoach, Collin M. Blakely, Kimberly C. Banks, Benjamin Levy, Ben M. Chue, Victoria M. Raymond, Anh T. Le, Christine E. Lee, Joseph Diaz, Saiama N. Waqar, William T. Purcell, Dara L. Aisner, Kurtis D. Davies, Richard B. Lanman, Alice T. Shaw, Robert C. Doebele
CLINICAL CANCER RESEARCH
(2018)
Meeting Abstract
Oncology
L. Wirth, A. Drilon, C. Albert, A. Farago, Wel-Diery, P. Ma, D. Sohal, L. Raez, C. Baik, M. S. Brose, R. Doebele, M. Cox, N. Ku, D. Hong
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2018)
Article
Oncology
Tyler P. Robin, D. Ross Camidge, Kelly Stuhr, Sameer K. Nath, Robert E. Breeze, Jose M. Pacheco, Arthur K. Liu, Laurie E. Gaspar, W. Thomas Purcell, Robert C. Doebele, Brian D. Kavanagh, Chad G. Rusthoven
JOURNAL OF THORACIC ONCOLOGY
(2018)
Article
Oncology
Sinead A. Noonan, Tejas Patil, Dexiang Gao, Gentry G. King, Jessica R. Thibault, Xian Lu, Paul A. Bunn, Robert C. Doebele, W. Thomas Purcell, Anna E. Baron, D. Ross Camidge
JOURNAL OF THORACIC ONCOLOGY
(2018)
Article
Oncology
Kurtis D. Davies, Anh T. Le, Jamie Sheren, Hala Nijmeh, Katherine Gowan, Kenneth L. Jones, Marileila Varella-Garcia, Dara L. Aisner, Robert C. Doebele
JOURNAL OF THORACIC ONCOLOGY
(2018)
Article
Oncology
Thereasa A. Rich, Karen L. Reckamp, Young Kwang Chae, Robert C. Doebele, Wade T. Iams, Michael Oh, Victoria M. Raymond, Richard B. Lanman, Jonathan W. Riess, Thomas E. Stinchcombe, Vivek Subbiah, David R. Trevarthen, Stephen Fairclough, Jennifer Yen, Oliver Gautschi
CLINICAL CANCER RESEARCH
(2019)
Article
Health Care Sciences & Services
Robert C. Doebele, Laura Perez, Huong Trinh, Michael Martinec, Reynaldo Martina, Todd Riehl, Matthew G. Krebs, Neal J. Meropol, William B. Wong, Gracy Crane
Summary: Direct comparative evidence for rare diseases in prospective randomized trials is challenging, and real-world cohorts provide supplementary control populations. In this study, it was found that entrectinib treatment in clinical trials may be associated with longer time-to-treatment discontinuation (TTD) compared to a real-world crizotinib-treated population.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2021)
Article
Oncology
T. L. Peters, T. Patil, A. T. Le, K. D. Davies, P. M. Brzeskiewicz, H. Nijmeh, L. Bao, D. R. Camidge, D. L. Aisner, R. C. Doebele
Summary: EGFR mutant non-small cell lung cancer patients initially respond well to EGFR-targeted therapy but often develop acquired resistance, which requires broad molecular testing to understand the resistance mechanisms and develop new treatment options.
NPJ PRECISION ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Varsha Ananthapadmanabhan, Thomas C. Frost, Kara M. Soroko, Aine Knott, Brianna J. Magliozzi, Prafulla C. Gokhale, Vijaya G. Tirunagaru, Robert C. Doebele, James A. DeCaprio
Summary: In this study, the efficacy of milademetan, an MDM2 inhibitor, was assessed in various MCC models, showing significant inhibition on WT p53 MCC tumors. Useful in vitro and in vivo models for future MCC studies were also reported.
Meeting Abstract
Oncology
Jordi Rodon Ahnert, Matthew H. Taylor, Eileen Mary O'Reilly, Jingsong Zhang, Robert Charles Doebele, Yong Ben, Leslie L. Sharp, William J. Boyle, Cathy Chang, Gerhard Frey, Wei Chen, Michael Melnick, Jay M. Short, Howard A. Burris
JOURNAL OF CLINICAL ONCOLOGY
(2018)
